↓ Skip to main content

Dove Medical Press

Article Metrics

Impact and prevention of severe exacerbations of COPD: a review of the evidence

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, October 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news
1 news outlet
twitter
8 tweeters
facebook
2 Facebook pages
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
130 Dimensions

Readers on

mendeley
274 Mendeley
Title
Impact and prevention of severe exacerbations of COPD: a review of the evidence
Published in
International Journal of Chronic Obstructive Pulmonary Disease, October 2017
DOI 10.2147/copd.s139470
Pubmed ID
Authors

David MG Halpin, Marc Miravitlles, Norbert Metzdorf, Bartolomé Celli

Abstract

Severe exacerbations of COPD, ie, those leading to hospitalization, have profound clinical implications for patients and significant economic consequences for society. The prevalence and burden of severe COPD exacerbations remain high, despite recognition of the importance of exacerbation prevention and the availability of new treatment options. Severe COPD exacerbations are associated with high mortality, have negative impact on quality of life, are linked to cardiovascular complications, and are a significant burden on the health-care system. This review identified risk factors that contribute to the development of severe exacerbations, treatment options (bronchodilators, antibiotics, corticosteroids [CSs], oxygen therapy, and ventilator support) to manage severe exacerbations, and strategies to prevent readmission to hospital. Risk factors that are amenable to change have been highlighted. A number of bronchodilators have demonstrated successful reduction in risk of severe exacerbations, including long-acting muscarinic antagonist or long-acting β2-agonist mono- or combination therapies, in addition to vaccination, mucolytic and antibiotic therapy, and nonpharmacological interventions, such as pulmonary rehabilitation. Recognition of the importance of severe exacerbations is an essential step in improving outcomes for patients with COPD. Evidence-based approaches to prevent and manage severe exacerbations should be implemented as part of targeted strategies for disease management.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 274 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 274 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 42 15%
Other 32 12%
Researcher 27 10%
Student > Bachelor 21 8%
Student > Ph. D. Student 20 7%
Other 54 20%
Unknown 78 28%
Readers by discipline Count As %
Medicine and Dentistry 91 33%
Nursing and Health Professions 39 14%
Pharmacology, Toxicology and Pharmaceutical Science 13 5%
Agricultural and Biological Sciences 11 4%
Biochemistry, Genetics and Molecular Biology 7 3%
Other 23 8%
Unknown 90 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 February 2022.
All research outputs
#1,680,880
of 21,814,108 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#138
of 2,261 outputs
Outputs of similar age
#40,874
of 342,463 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#6
of 57 outputs
Altmetric has tracked 21,814,108 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,261 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,463 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.